2025-12-15 – Press Releases – www.prnewswire.com
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ — Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE…
